multiple sclerosis ms autoimmune disease insulating covers nerve cells brain spinal cord damage disrupts ability parts nervous system transmit signals resulting range signs symptoms including physical mental sometimes psychiatric specific symptoms include double vision vision loss eye pain muscle weakness loss sensation ms takes several forms new symptoms either occurring isolated attacks relapsing forms building time progressive relapsing forms ms attacks symptoms may disappear completely although permanent neurological problems often remain especially disease progressive forms ms bodily function slowly deteriorates disability worsens symptoms manifest steadily continue disease left cause unclear underlying mechanism thought either destruction immune system failure myelinproducing proposed causes include immune dysregulation genetics environmental factors viral ms usually diagnosed based presenting signs symptoms results supporting medical cure multiple sclerosis current treatments aimed mitigating inflammation resulting symptoms acute flares prevention attacks diseasemodifying physical occupational along patientcentered symptom management help peoples ability function longterm outcome difficult predict better outcomes often seen women develop disease early life relapsing course initially experienced multiple sclerosis common immunemediated disorder affecting central nervous nearly one million people united states ms million people affected globally rates varying widely different regions among different disease usually begins ages twice common women ms first described french neurologist jeanmartin name multiple sclerosis short multiple cerebrospinal sclerosis refers numerous glial scars sclerae essentially plaques lesions develop white matter brain spinal ms lesions affect part central nervous system person ms almost neurological symptom sign referable central nervous system autonomic visual motor sensory problems specific symptoms determined locations lesions within nervous system may include focal loss sensitivity andor changes sensation limbs feeling tingling pins needles numbness limb motor weaknesspain blurred pronounced reflexes muscle spasms difficulty ambulation difficulties coordination balance ataxia problems speech swallowing visual problems optic neuritis manifesting eye pain vision nystagmus manifesting double vision fatigue bladder bowel difficulties urinary andor fecal incontinence retention among multiple sclerosis advanced walking difficulties occur risk falling difficulties thinking emotional problems depression unstable mood also primary deficit cognitive function people ms experience slowed informationprocessing speed memory also commonly affected executive function less commonly intelligence language semantic memory usually preserved level cognitive impairment varies considerably people uhthoffs phenomenon worsening symptoms due exposure higherthanusual temperatures lhermittes sign electrical sensation runs back bending neck particularly characteristic ms although may always another presenting manifestation rare highly suggestive demyelinating process ms bilateral intranuclear ophthalmoplegia patient experiences double vision attempting move gaze right main measure disability severity expanded disability status scale edss measures multiple sclerosis functional composite increasingly used edss also correlated falls people popular measure edss criticized limitations relying much condition begins cases clinically isolated syndrome cis number days motor sensory problems optic symptoms related brainstem dysfunction remaining one previous course symptoms occurs two main patterns initially either episodes sudden worsening last days months called relapses exacerbations bouts attacks flareups followed improvement cases gradual worsening time without periods recovery combination two patterns may also people may start relapsing remitting course becomes progressive later relapses usually predictable occurring without exacerbations rarely occur frequently twice per relapses however preceded common triggers occur frequently spring similarly viral infections common cold influenza gastroenteritis increase stress may also trigger women ms become pregnant experience fewer relapses however first months delivery risk overall pregnancy seem influence longterm many events found affect rates relapse requiring hospitalization including breast physical uhthoffs ms may prodromal phase years leading ms manifestation characterized psychiatric issues cognitive impairment increased use cause ms unknown believed occur result combination immune addition genetic environmental factors infectious failure central peripheral nervous system clearance autoreactive immune cells implicated development thymus responsible immune systems central tolerance autoreactive tcells killed without released circulation via similar mechanism autoreactive bcells bone marrow killed autoreactive tcells bcells able escape defense mechanisms peripheral immune tolerance defenses take action preventing causing disease however additional lines defense still detail immune dysregulations role ms provided pathophysiology section article well one hypothesis infection widespread microbe contributes disease development geographic distribution organism influences epidemiology two opposing versions hypothesis include hygiene hypothesis prevalence hypothesis former hygiene hypothesis proposes exposure certain infectious agents early life protective disease response late encounter prevalence hypothesis proposes early persistent silent infection increases risk disease thus disease common infectious agent common cases many years cause evidence virus cause include presence oligoclonal bands brain cerebrospinal fluid people ms association several viruses human demyelinating encephalomyelitis occurrence demyelination animals caused viral epsteinbarr herpes virus ebv cause infectious mononucleosis infects adults combination genetic environmental factors compelling epidemiological mechanistic evidence causal role ebv multiple sclerosis though small proportion infected ebv later develop study individuals united states military total population greater million compared people developed ms military service matched controls develop ms observation period study found increased risk developing ms infection ebv find increased risk infection viruses including similarly transmitted cytomegalovirus finding strongly suggests ebv plays role onset ms although ebv alone may insufficient cause ms considered hereditary disease several genetic variations shown increase genes appear higher levels expression microglial cells expected probability developing disease higher relatives affected person greater risk among closely identical twin affected individual chance developing ms nonidentical twin sibling even lower chance half parents affected risk children times general ms also common ethnic groups specific genes linked ms include differences human leukocyte antigen hla group genes chromosome serves major histocompatibility complex differences hla region related susceptibility known since region also implicated development autoimmune diseases diabetes type systemic lupus consistent finding association higher risk developing multiple sclerosis mhc allele present us population northern european loci shown protective effect hla differences account estimated genetic modern genetic methods genomewide association studies revealed least variants outside hla locus modestly increase probability prevalence ms geographic standpoint resembles gradient ms common people live farther equator eg live northern regions world although exceptions exceptions include ethnic groups low risk live far equator sami amerindians canadian hutterites new zealand canadas well groups relatively high risk live closer equator inland palestinians cause geographical pattern clear although exposure ultraviolet b uvb radiation vitamin levels proposed potential live northern regions world thought less exposure uvb radiation subsequently lower levels vitamin known risk factor developing inversely live areas relatively higher sun exposure subsequently increased uvb radiation decreased risk developing gradient incidence still ms common regions northern european geographic variation may simply reflect global distribution highrisk relationship season birth ms lends support idea fewer people born northern hemisphere november compared may affected later environmental factors may play role childhood several studies finding people move different region world age acquire new regions risk ms migration takes place age persons retain risk home evidence indicates effect moving may still apply people older smoking may independent risk factor stress may risk factor although evidence support association occupational exposures organic evaluated clear conclusions vaccinations studied causal factors studies though show several possible risk factors diet hormone intake evaluated evidence relation disease sparse gout occurs less would expected lower levels uric acid found people ms led theory uric acid protective although exact importance remains obesity adolescence young adulthood risk factor three main characteristics ms formation lesions central nervous system also called plaques inflammation destruction myelin sheaths neurons features interact complex yet fully understood manner produce breakdown nerve tissue turn signs symptoms ms believed immunemediated disorder develops interaction individuals genetics yet unidentified environmental damage believed caused least part attack nervous system persons immune briefly detailed causes section article ms currently thought stem failure bodys immune system kill autoreactive tcells currently tcell subpopulations thought drive development ms autoreactive tcells helper tcells cells autoreactive tcells produce substances called cytokines induce inflammatory immune response cns leading development recently however role autoreactive bcells elucidated evidence contribution development ms implicated presence oligoclonal igg bands antibodies produced bcells csf patients presence oligoclonal bands used supportive evidence clinching diagnosis similarly described bcells also produce cytokines induce inflammatory immune response via activation autoreactive higher levels autoreactive bcells associated increased number lesions neurodegeneration well worse name multiple sclerosis refers scars sclerae better known plaques lesions form nervous system lesions commonly affect white matter optic nerve brain stem basal ganglia spinal cord white matter tracts close lateral function white matter cells carry signals grey matter areas processing done rest body peripheral nervous system rarely specific ms involves loss oligodendrocytes cells responsible creating maintaining fatty myelin helps neurons carry electrical signals action results thinning complete loss myelin disease advances breakdown axons neurons myelin lost neuron longer effectively conduct electrical repair process called remyelination takes place early phases disease oligodendrocytes unable completely rebuild cells myelin repeated attacks lead successively less effective remyelinations scarlike plaque built around damaged scars origin symptoms attack magnetic resonance imaging mri often shows new could indicate number lesions exist brain capable repairing without producing noticeable another process involved creation lesions abnormal increase number astrocytes due destruction nearby number lesion patterns apart demyelination sign disease inflammation fitting immunological explanation inflammatory process caused cells kind lymphocytes plays important role bodys cells gain entry brain result disruptions barrier cells recognize myelin foreign attack explaining cells also called autoreactive attack myelin starts inflammatory processes trigger immune cells release soluble factors like cytokines antibodies breakdown bloodbrain barrier turn causes number damaging effects swelling activation macrophages activation cytokines destructive inflammation potentially reduce transmission information neurons least three soluble factors released might stop neurotransmission intact neurons factors could lead enhance loss myelin may cause axon break barrier bbb part capillary system prevents entry cells central nervous system may become permeable types cells secondary infection virus bacteria repairs typically infection cleared cells may remain trapped inside gadolinium cross normal bbb gadoliniumenhanced mri used show bbb multiple sclerosis typically diagnosed based presenting signs symptoms combination supporting medical imaging laboratory difficult confirm especially early since signs symptoms may similar medical mcdonald criteria focus clinical laboratory radiologic evidence lesions different times different areas commonly used method schumacher poser criteria mostly historical mcdonald criteria states patients multiple sclerosis lesions disseminated time dit disseminated space dis ie lesions appeared different areas brain different times single test including biopsy provide definitive magnetic resonance imaging mri brain spine may show areas demyelination lesions plaques gadolinium administered intravenously contrast agent highlight active plaques elimination demonstrate existence historical lesions associated symptoms moment central vein signs cvss proposed good indicator ms comparison conditions causing white one small study found fewer cvss older hypertensive research cvs biomarker ms brain atrophy seen indicator testing cerebrospinal fluid obtained lumbar puncture provide evidence chronic inflammation central nervous system cerebrospinal fluid tested oligoclonal bands igg electrophoresis inflammation markers found people several diseases present similarly medical professionals use patients specific presentation history exam findings make individualized differential red flags findings suggest alternate diagnosis although rule ms red flags include patient younger older less hours symptoms involvement multiple cranial nerves involvement organs outside nervous system atypical lab exam emergency setting important rule stroke bleeding intractable vomiting severe optic bilateral optic raises suspicion neuromyelitis optica spectrum disorder infectious diseases may look similar multiple sclerosis include hiv lyme disease syphilis autoimmune diseases include sarcoidosis lupus guillainbarré syndrome acute disseminated encephalomyelitis behçets disease psychiatric conditions anxiety conversion disorder may also present similar way rare diseases differential include cns lymphoma congenital leukodystrophies antimogassociated several phenotypes commonly termed types patterns progression described phenotypes use past course disease attempt predict future course important prognosis also treatment decisions international advisory committee clinical trials ms describes four types ms revised known lublin cis characterised single lesion seen mri associated signs andor symptoms found ms due mcdonald criteria completely fit criteria diagnosed ms hence named clinically isolated syndrome cis seen first episode demyelination central nervous system classified cis attack must last least hours caused inflammation demyelination central nervous patients suffer cis may may go develop ms persons experience cis later develop rrms characterized unpredictable relapses followed periods months years relative quiet remission new signs disease activity deficits occur attacks may either resolve leave problems latter attacks common longer person describes initial course individuals ppms occurs roughly individuals disease remission initial characterized progression disability onset occasional minor remissions usual age onset primary progressive subtype later relapsingremitting subtype similar age secondary progressive usually begins rrms around years spms occurs around initial rrms eventually progressive neurologic decline acute attacks without definite periods occasional relapses minor remissions may common length time disease onset conversion rrms spms independently types published ms associations regulatory agencies fda often consider special courses trying reflect clinical trials results approval documents examples could highly active ms active secondary ms similar old rapidly progressing also deficits always resolving attacks sometimes referred benign although people still build degree disability long hand term malignant multiple sclerosis used describe people ms reached significant level disability short international panel published standardized definition course atypical variants ms described include tumefactive multiple sclerosis balo concentric sclerosis schilders diffuse sclerosis marburg multiple sclerosis debate remains whether ms variants different diseases previously considered ms variants devics disease considered outside ms although cure multiple sclerosis found several therapies proven helpful several effective treatments decrease number attacks rate primary aims therapy returning function attack preventing new attacks preventing disability starting medications generally recommended people first attack two lesions seen first approved medications used treat ms modestly effective though poorly tolerated many adverse several treatment options better safety tolerability profiles improving prognosis ms medical treatment medications used management ms several adverse effects alternative treatments pursued people despite shortage supporting evidence efficacy symptomatic attacks administration high doses intravenous corticosteroids methylprednisolone usual oral corticosteroids seeming similar efficacy safety although effective short term relieving symptoms corticosteroid treatments appear significant impact longterm longterm benefit unclear optic neuritis consequences severe attacks respond corticosteroids might treatable multiple diseasemodifying medications approved regulatory agencies rrms modestly effective decreasing number glatiramer acetate firstline roughly equivalent reducing relapses approximately earlyinitiated longterm therapy safe improves treatment cis interferons decreases chance progressing clinical efficacy interferons glatiramer acetate children estimated roughly equivalent role newer agents teriflunomide dimethyl yet entirely making firm conclusions best treatment difficult especially regarding benefit safety early treatment given lack studies directly comparing diseasemodifying therapies longterm monitoring patient relative effectiveness different treatments unclear compared placebo small number direct comparisons interferons glatiramer acetate indicate similar effects small differences effects relapse rate disease progression mri alemtuzumab natalizumab fingolimod may effective drugs reducing relapses short term people natalizumab interferon rebif may reduce relapses compared placebo interferon avonex interferon betaseron glatiramer acetate mitoxantrone may also prevent evidence relative effectiveness reducing disability progression medications associated adverse effects may influence risk benefit ublituximab approved medical use united states december overview medications available ms source multiple sclerosis mitoxantrone first medication approved secondary progressive population tentative evidence supports mitoxantrone moderately slowing progression disease decreasing rates relapses two new approved medications continue emerge modern medicine march fda approved ocrelizumab treatment primary progressive ms adults first drug gain requirements several phase iv clinical also used treatment relapsing forms multiple sclerosis include clinically isolated syndrome relapsingremitting disease active secondary progressive disease according cochrane review ocrelizumab may reduce worsening symptoms primary progressive ms probably increases unwanted effects makes little difference number serious unwanted siponimod cladribine approved united states treatment secondary progressive multiple sclerosis subsequently ozanimod approved ponesimod approved approved management cis relapsing ms spms us rrms diseasemodifying treatments several adverse effects one common irritation injection site glatiramer acetate interferons subcutaneous injections intramuscular time visible dent injection site due local destruction fat tissue known lipoatrophy may interferons may produce flulike people taking glatiramer experience postinjection reaction flushing chest tightness heart palpitations anxiety usually lasts less thirty dangerous much less common liver damage systolic dysfunction infertility acute myeloid leukemia progressive multifocal leukoencephalopathy occurring natalizumab occurring people fingolimod may give rise hypertension slowed heart rate macular edema elevated liver enzymes reduction lymphocyte tentative evidence supports shortterm safety teriflunomide common side effects including headaches fatigue nausea hair loss limb also reports liver failure pml use dangerous fetal common side effects dimethyl fumarate flushing gastrointestinal dimethyl fumarate may lead reduction white blood cell count reported cases opportunistic infections medications neurorehabilitation shown improve symptoms though neither changes course symptoms good response medication bladder spasticity others little equipment catheters neurogenic bladder dysfunction mobility aids helpful improving functional status multidisciplinary approach important improving quality life however difficult specify core team many health services may needed different points multidisciplinary rehabilitation programs increase activity participation people ms influence impairment studies investigating information provision support patient understanding participation suggest interventions written information decision aids coaching educational programmes may increase knowledge evidence effect decision making quality life mixed low limited evidence overall efficacy individual therapeutic though good evidence specific approaches psychological therapies cognitive training alone combined neuropsychological interventions may show positive effects memory attention though firm conclusions possible given small sample numbers variable methodology interventions outcome effectiveness palliative approaches addition standard care uncertain due lack effectiveness interventions including exercise specifically prevention falls people ms uncertain evidence effect balance function cognitive behavioral therapy shown moderately effective reducing ms evidence effectiveness nonpharmacological interventions chronic pain insufficient recommend interventions alone however use combination medications may evidence aquatic therapy beneficial spasticity associated ms difficult manage progressive fluctuating course although firm conclusion efficacy reducing spasticity pt interventions safe beneficial option patients multiple sclerosis physical therapy including vibration interventions electrical stimulation exercise therapy standing therapy radial shock wave therapy rswt beneficial limiting spasticity helping limit excitability increasing range people ms may use complementary alternative medicine although percentages vary depending alternative medicine regarding characteristics users frequently women ms longer time tend disabled lower levels satisfaction conventional evidence effectiveness treatments cases weak treatments unproven benefit used people ms include dietary supplementation vitamin relaxation techniques herbal medicine including medical hyperbaric oxygen selfinfection hookworms reflexology evidence suggests vitamin supplementation irrespective form dose provides benefit people ms includes measures relapse recurrence disability mri lesions effects quality life fatigue insufficient evidence supporting highdose evidence increased disease activity higher risk relapse availability treatments modify course multiple sclerosis beginning known diseasemodifying therapies dmts improved prognosis treatments reduce relapses slow progression prognosis ms depends subtype disease considerable individual variation progression relapsing ms common subtype cohort study found median years onset one ten needed walking aid almost two ten transitioned secondary progressive ms form characterized progressive treatments available relapses eliminated substantially reduced however silent progression disease still addition secondary progressive ms spms small proportion people ms experience progressive decline onset known primary progressive ms ppms treatments approved use relapsing ms fewer treatments lower efficacy progressive forms prognosis progressive ms worse faster accumulation disability though considerable individual untreated ppms median time onset requiring walking aid estimated seven spms cohort study reported people required walking aid average five years onset spms chair bedbound average fifteen diagnosis ms characteristics predict worse course male sex older age greater disability time diagnosis female sex associated higher relapse biomarker accurately predict disease progression every spinal cord lesions abnormalities mri brain atrophy predictive worse course though brain atrophy predictor disease course experimental used clinical practice early treatment leads better prognosis higher relapse frequency treated dmts associated poorer longitudinal population study conducted norway found shorter life expectancy ms compared general population rise survival ms observation period median life expectancy rrms patients years years ppms compared years general population life expectancy men years shorter ms common autoimmune disorder central nervous latest estimation total number people ms million globally prevalence per people moreover prevalence varies widely different regions around africa people per diagnosed ms compared south east asia prevalence per per americas per increasing rates ms may explained simply better studies populational geographical patterns led number theories ms usually appears adults late twenties early thirties rarely start childhood years primary progressive subtype common people similarly many autoimmune disorders disease common women trend may globally two times common women men ratio women men ms high citation needed children even common females people fifty affects males females almost robert carswell british professor pathology jean cruveilhier french professor pathologic anatomy described illustrated many diseases clinical details identify separate specifically carswell described injuries found remarkable lesion spinal cord accompanied microscope swiss pathologist georg eduard rindfleisch noted inflammationassociated lesions distributed around blood french neurologist jeanmartin charcot first person recognize multiple sclerosis distinct disease summarizing previous reports adding clinical pathological observations charcot called disease sclerose en plaques first attempt establish set diagnostic criteria also due charcot published known charcot triad consisting nystagmus intention tremor telegraphic speech scanning charcot also observed cognition changes describing patients marked enfeeblement memory conceptions formed diagnosis based charcot triad clinical observation schumacher made first attempt standardize criteria introducing fundamental requirements dissemination lesions time dit space dis signs symptoms explained better another disease dit dis requirement later inherited poser mcdonald criteria whose revision century theories cause pathogenesis developed effective treatments began appear since beginning century refinements concepts taken place revision mcdonald criteria allowed diagnosis ms one proved lesion us national multiple sclerosis society nmss advisory committee clinical trials defined first version clinical phenotypes use first version provided standardized definitions four ms clinical courses relapsingremitting rr secondary progressive sp primary progressive pp progressive relapsing pr pr dropped cis three years later revision phenotypes disease course forced consider cis one phenotypes ms making obsolete expressions like conversion cis organizations proposed later new clinical phenotypes like hams highly active several historical accounts people probably ms lived shortly disease described charcot young woman called halldora lived iceland around suddenly lost vision mobility recovered seven days saint lidwina schiedam dutch nun may one first clearly identifiable people ms age death intermittent pain weakness legs vision loss symptoms typical cases led proposal viking gene hypothesis dissemination augustus frederick deste son prince augustus frederick duke sussex lady augusta murray grandson george iii united kingdom almost certainly ms deste left detailed diary describing years living disease diary began ended although remained unknown symptoms began age sudden transient visual loss amaurosis fugax funeral friend disease developed weakness legs clumsiness hands numbness dizziness bladder disturbance erectile dysfunction began use wheelchair despite illness kept optimistic view another early account ms kept british diarist w n p barbellion pen name bruce frederick cummings maintained detailed log diagnosis diary published journal disappointed charles dickens keen observer described possible bilateral optic neuritis reduced contrast vision uhthoff phenomenon main female character bleak house esther pathogenesis ms relates epsteinbarr virus ebv actively investigated diseasemodifying therapies understanding risk factors combine ebv initiate ms sought whether ebv cause ms might better understood ebv vaccine developed shown prevent ms even though variety studies showed connection ebv infection later development multiple sclerosis mechanisms behind correlation completely clear several theories proposed explain relationship two diseases thought involvement ebvinfected involvement antiebna antibodies appear significantly higher multiple sclerosis patients play crucial role development supported fact treatment bcells eg ocrelizumab reduces symptoms multiple sclerosis annual relapses appear less frequently disability progression stanford university study shown ebv infection molecular mimicry occur immune system produce antibodies protein time able bind glialcam myelin additionally observed phenomenon uncommon healthy individuals often detected multiple sclerosis patients bcells trafficking brain spinal cord producing oligoclonal antibody bands majority oligoclonal bands affinity viral protein crossreactive glialcam antibodies abundant approximately multiple sclerosis patients worsen autoimmune demyelination leads consequently pathophysiologocal exacerbation disease furthermore intrathecal oligoclonal expansion constant somatic hypermutation unique multiple sclerosis compared neuroinflammatory diseases study also abundance antibodies ighv genes measured appears connected disease progress antibodies binding high affinity glialcam process actively thriving demyelination probable bcells expressing ighv genes entered csf underwent affinity maturation facing glialcam led consequently production high affinity antiglialcam antibodies additionally shown eae mouse model immunization lead strong bcell response glialcam worsened two members human endogenous retrovirusesw hervw family namely msassociated retrovirus msrv may cofactors ms immunopathogenesis hervs constitute human genome epignetically silent reactivated exogenous viruses proinflammatory conditions andor oxidative medications influence voltagegated sodium ion channels investigation potential neuroprotective strategy hypothesized role sodium pathological process leading axonal injury accumulating disability insufficient evidence effect sodium channel blockers people ms clinically defined entity several atypical presentations autoantibodies found atypical ms cases giving birth separate disease families restricting previously wider concept ms autoantibodies found neuromyelitis optica nmo previously considered ms variant spectrum diseases named nmosd nmo spectrum diseases diseases cases ms presenting antimog autoantibodies mainly overlapping marburg variant antimog autoantibodies found also present adem second spectrum separated diseases considered spectrum named inconsistently across different authors normally something similar antimog demyelinating third kind autoantibodies accepted several antineurofascin autoantibodies damage ranvier nodes neurons antibodies related peripheral nervous demyelination also found chronic progressive ppms combined central peripheral demyelination ccpd considered another atypical ms addition significance autoantibodies ms four different patterns demyelination reported opening door consider ms heterogeneous since disease progression result degeneration neurons roles proteins showing loss nerve tissue neurofilaments tau nacetylaspartate improvement neuroimaging techniques positron emission tomography pet mri carry promise better diagnosis prognosis predictions regarding mri several techniques already shown usefulness research settings could introduced clinical practice doubleinversion recovery sequences magnetization transfer diffusion tensor functional magnetic resonance techniques specific disease existing ones still lack standardization acquisition protocols creation normative particularly case proton magnetic resonance spectroscopy number methodological variations observed literature may underlie continued inconsistencies central nervous system metabolic abnormalities particularly nacetyl aspartate myoinositol choline glutamate gaba gsh observed multiple sclerosis techniques development include contrast agents capable measuring levels peripheral macrophages inflammation neuronal techniques measure iron deposition could serve determine role feature ms cerebral hospitalization rate found higher among individuals ms infection pooled infection rate estimated pooled prevalence death hospitalized individuals ms estimated one emerging hypothesis referred hygiene hypothesis suggests earlylife exposure infectious agents helps develop immune system reduces susceptibility allergies autoimmune disorders including ms germfree mice infected transplanted fecal matter ms patients exhibit increased risk developing eae animal model citation needed hygiene hypothesis linked ms microbiome also proposed certain bacteria found gut use molecular mimicry infiltrate brain via gutbrain axis initiating inflammatory response increasing bloodbrain barrier permeability vitamin levels also correlated ms lower levels vitamin correspond increased risk ms suggesting reduced prevalence tropics area vitamin drich sunlight strengthening impact geographical location ms ms mechanisms begin peripheral autoreactive effector cells get activated move cns antigenpresenting cells localize reactivation autoreactive effector cells entered cns attracting cells macrophages form inflammatory citation needed ms patients macrophages microglia assemble locations demyelination neurodegeneration actively occurring microglial activation apparent normalappearing white matter ms astrocytes generate neurotoxic chemicals like nitric oxide tnfα attract neurotoxic inflammatory monocytes cns responsible astrogliosis scarring prevents spread neuroinflammation kills neurons inside scarred source needed disease httpsenwikipediaorgwikimultiplesclerosis